Cardiovascular events in EGFR-mutation non-small-cell lung cancer patients on osimertinib
Osimertinib appears to be associated with an increase in cardiac abnormalities. Given the association between this medication exposure and the observed cardiac toxicities, use of osimertinib may entail closer cardiac monitoring of electrocardiogram (ECG) and echocardiogram abnormalities.
Authors
- Syed Farhan Ahmad (ORCID: https://orcid.org/0000-0002-6596-0980)
- Brijesh Patel (ORCID: https://orcid.org/0000-0001-8973-8228)
- Karthik Gonuguntla (ORCID: https://orcid.org/0000-0002-5607-7993)
- Samuel Mensah (ORCID: https://orcid.org/0009-0004-6963-9221)
- Rutu Raval
- Waleed Alruwaili
Institutions
- West Virginia University (US)
Publication Details
- Journal
- European Journal of Hospital Pharmacy
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1136/ejhpharm-2024-004319
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00